COPD
Conditions
Keywords
Pulmonary Rehabilitation, Neutrophils
Brief summary
COPD is characterised by irreversible airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response. This inflammation can be amplified with flare-ups that are commonly seen in COPD patients. Pulmonary rehabilitation is one of the most effective methods of managing chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation has been seen to induce improvements in functional capacity and quality. In healthy individuals, exercise has been shown to induce an anti-inflammatory response when performed regularly. However, the effects of exercise on inflammation in COPD are unclear. Our initial CIMPRES-COPD study has looked into the effects of short-term exercise, as part of pulmonary rehabilitation, on inflammation. However, this trial will examine the inflammatory response in COPD patients who are most active following pulmonary rehabilitation against those who are least active. This study will split participants into 2 groups according to physical activity level following pulmonary rehabilitation. We will recruit 40 COPD patients who provided a sample in the initial CIMPRES-COPD study to explore inflammatory responses in those who are most active and least active. By better understanding the mechanisms of how long-term physical activity levels affects inflammation in COPD, we could design better interventions to increase physical activity levels following pulmonary rehabilitation.
Interventions
COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
Sponsors
National Health Service, United Kingdom
University of Lincoln
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with any severity of COPD (according to British Thoracic Society criteria, i.e. \>10 pack year smoking history and post bronchodilator spirometry FEV1/FVC ratio \<0.70 and FEV\<80%) * Previously enrolled on pulmonary rehabilitation providing at least one sample for the CIMPRES-COPD trial.
Exclusion criteria
* Any unstable ongoing cardiovascular events. * Other active inflammatory conditions (e.g. rheumatoid arthritis, cancer). * Known asthma, allergic rhinitis or other respiratory disease (bronchiectasis, pulmonary fibrosis).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cytokines | May 2018 - August 2018 | Changes in concentration of inflammatory cytokines in the plasma of all participants using ELISA's (mg/L) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Leukocyte count | May 2018 - August 2018 | Changes in total and differential leukocyte count in all participants (10\^9.L-1) |
| Cell function | May 2018 - August 2018 | Changes in function of the following cells: myeloperoxidase, neutrophil elastase, MMP-8, MMP-9, TNF-a in the plasma of all participants using ELISA's (mg/L) |
| Cell sensitivity to corticosteroids | May 2018 - August 2018 | Changes in cell sensitivity to corticosteroids and forskolin in all participants (expressed as fold increase from not treated samples) |
Countries
United Kingdom
Outcome results
None listed